EGRX - Eagle Pharmaceuticals Non-GAAP EPS of $1.11 beats by $0.28 revenue of $60.7M misses by $3.56M
2023-03-13 06:54:27 ET
- Eagle Pharmaceuticals press release ( NASDAQ: EGRX ): Q4 Non-GAAP EPS of $1.11 beats by $0.28 .
- Revenue of $60.7M (+43.4% Y/Y) misses by $3.56M .
-
Q4 2022 RYANODEX net product sales were $7.2 million, compared to $6.1 million in the fourth quarter of 2021.
Q4 2022 BELRAPZO net product sales were $11.0 million, compared to $5.5 million in the fourth quarter of 2021.
Q4 2022 PEMFEXY net product sales were $12.1 million and vasopressin net product sales were $3.6 million
- As of December 31, 2022, Eagle had $55.3 million in cash and cash equivalents
-
2023 Guidance:
- Adjusted EBITDA of $74.0-$80.0 million 1
- Adjusted non-GAAP earnings per share of $4.20-$4.53 vs consensus of $3.99
- Adjusted non-GAAP R&D expense of $41.0-$45.0 million 1
- Adjusted non-GAAP SG&A expense of $86.0-$90.0 million 1
For further details see:
Eagle Pharmaceuticals Non-GAAP EPS of $1.11 beats by $0.28, revenue of $60.7M misses by $3.56M